Q2 FY2026 · ended Jun 30, 2026 · Revenue $4.94M, -15.2% YoY · Filed Aug 13, 2026
MaxCyte, Inc. (MXCT) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $4.9 million and a net loss of $8.9 million. Free cash flow was -$4.7 million. As of Jun 30, 2026 it held $141.9 million in cash and investments and $17.3 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MXCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1287098
- Former names
- MAXCYTE INC (until Sep 18, 2008)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $4.9M | $4.5M | $4.8M | $4.6M | $5.8M |
| Operating income | -$10.2M | -$6.2M | -$11.2M | -$14.1M | -$14.2M |
| Net income | -$8.9M | -$4.8M | -$9.6M | -$12.4M | -$12.4M |
| Diluted EPS | -$0.08 | -$0.04 | -$0.09 | -$0.12 | -$0.12 |
| Operating cash flow | -$4.7M | -$8.2M | -$2.7M | -$7.5M | -$9.9M |
| Free cash flow | -$4.7M | -$8.2M | -$2.9M | -$7.8M | -$10.4M |
| Total assets | $184.7M | $194.5M | $202.5M | $213.5M | $219.8M |
| Total liabilities | $25.9M | $26.6M | $31.0M | $33.2M | $29.0M |
| Stockholders' equity | $158.8M | $167.9M | $171.5M | $180.3M | $190.7M |
| Cash and investments | $141.9M | $147.7M | $155.6M | $158.0M | $165.2M |
| Total debt | $17.3M | $17.5M | $17.9M | $18.2M | $18.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 14, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 16, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 336 MaxCyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.